New SBA proposal could open R&D funds to foreign-owned firms (Washington bureau)
Proposed rules for the Small Business Innovation Research program could allow foreign-owned companies to compete for these federal R&D awards, according to the Small Business Technology Council.
Sanofi inks diabetes partnership with Brigham (Boston Business Journal)
French drug maker Sanofi (NYSE: SNY) has entered into a research agreement with Brigham and Women's Hospital to study the immunology of Type 1 diabetes, focusing on a target that has shown promise in animal studies.
Biotech center launches crops commercialization center (Triangle Business Journal)
The North Carolina Biotechnology Center has launched a new Biotechnology Crops Commercialization Center, which will be led by Monsanto veteran Alan Kriz.Omeros will apply to FDA for trial of schizophrenia drug (Puget Sound Business Journal)
Seattle-based Omeros Corporation notified the Food and Drug Administration that the biotech company intends to submit an investigational new drug (IND) application this quarter for a medication expected to treat schizophrenia.
Medtronic may invest in India-based med-tech player (Minneapolis-St. Paul Business Journal)
Medtronic Inc. is negotiating an equity investment in Triviton Healthcare, a med-tech business based in India, reports theBusiness Standard.
Hemispherx seeks orphan status in Argentina for chronic fatigue drug (Philadelphia Business Journal)
Philadelphia-based Hemispherx Biopharma (NASDAQ:HEB) has filed a new drug application in Argentina for Ampligen, and is seeking orphan drug status for the product, which is intended to treat chronic fatigue syndrome.
Outgoing Impax CFO nets cash, health care benefits (San Francisco Business Times)
Departing Impax Laboratories Inc. CFO Arthur Koch Jr. will take a hefty benefits package with him.
Respironics announces voluntary recall (Pittsburgh Business Times)
Murrysville-based Respironics Inc. said it was voluntarily recalling about 85 ventilators suspected of possibly defective electronics.
No comments:
Post a Comment